Literature DB >> 19652644

A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.

Marco Righi1, Arianna Giacomini, Cristiana Lavazza, Daniela Sia, Carmelo Carlo-Stella, Alessandro M Gianni.   

Abstract

Experimental approaches currently used to quantify the activity of antiangiogenic treatments in cancer therapy do not generally address the importance of spatial distribution of microvessels in target tissues. We report a new computerized method to assess tumor vascularization by quantifying the distribution of functional microvessels as revealed by in vivo staining with sulfosuccinimidyl-6-(biotinamido) hexanoate. Our approach was based on pixel dilation of digital images of blood vessels and addressed the space-filling property of the vessel layouts. This was practically achieved computing the number of dilation cycles (Halo index) needed to permeate a pre-defined amount of each image. Our approach was validated on human tumor xenografts in nonobese diabetic/severe combined immunodeficient mice treated with the antiangiogenic drug sorafenib. For each experimental model, area normalization allowed the unbiased comparison of several hundreds of images showing different amounts of vascular tissue. In two different tumor types, comparison of Halo values showed statistically significant differences between control and sorafenib-treated samples. Conversely, this effect was not observed in samples from an additional xenograft known to resist the antiangiogenic treatment. By separating the analysis of vessel area from the quantification of vessel distributions, our approach can potentially contribute to a better evaluation of the antiangiogenic or vascular-disrupting activity of new drugs or treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652644     DOI: 10.1038/labinvest.2009.76

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  4 in total

1.  Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study.

Authors:  Keiko Yoshida; Tomihiko Hirokawa; Fuminori Moriyasu; Longzhong Liu; Guang-Jian Liu; Masahiko Yamada; Yasuharu Imai
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

2.  Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Authors:  Carmelo Carlo-Stella; Silvia L Locatelli; Arianna Giacomini; Loredana Cleris; Elena Saba; Marco Righi; Anna Guidetti; Alessandro M Gianni
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

3.  Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment.

Authors:  Hiroyuki Fukuda; Kazushi Numata; Koji Hara; Akito Nozaki; Masaaki Kondo; Makoto Chuma; Masayuki Nakano; Akinori Nozawa; Shin Maeda; Katsuaki Tanaka
Journal:  J Cancer       Date:  2018-06-14       Impact factor: 4.207

4.  (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies.

Authors:  Marco Righi; Arianna Giacomini; Loredana Cleris; Carmelo Carlo-Stella
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.